<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30314434</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1471-2407</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>18</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>12</Day>                    </PubDate>                </JournalIssue>                <Title>BMC cancer</Title>                <ISOAbbreviation>BMC Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study.</ArticleTitle>            <Pagination>                <MedlinePgn>975</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-018-4889-1</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In our previous study, colorectal cancer (CRC) patients with active Mycobacterium tuberculosis (MTB) tolerated concurrent anti-cancer chemotherapy (anti-CCT) and anti-MTB chemotherapy. In this study, we retrospectively confirmed the efficacy and safety of concurrent chemotherapy in a greater number of patients with different types of malignancies.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We enrolled 30 patients who were treated concurrently with anti-CCT and anti-MTB regimens between January 2006 and February 2016. Cancer and MTB treatments were administered according to the approved guidelines.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Patient demographics included: men/woman: 24/6; median age: 66.5 years; Eastern Cooperative Oncology Group performance status 0-1/2/3-4: 24/4/2; Stage IIB-IIIC/IV/recurrence: 6/22/2; lung cancer (LC)/CRC/other: 15/10/5; and MTB diagnosis (before or during anti-CCT): 20/10 (LC: 8/7; CRC: 8/2; other: 4/1). For anti-CCT, 23 patients received two cytotoxic agents with or without targeted agents and 7 patients received a single cytotoxic or targeted agent. The overall response rate was 36.7%. Regarding anti-MTB chemotherapy, 22 patients received a daily drug combination containing isoniazid, rifampicin, and ethambutol, plus pyrazinamide in 15 of the 22 patients, followed by daily isoniazid and rifampicin; the remaining 8 patients received other combinations. Hematological adverse events of Grade ≥ 3 were observed in 19 (67.9%) of 28 patients; laboratory data were lost for the remaining 2. Grade 3 lymphopenia and higher were significantly more frequent in LC compared to other malignancies (P &lt; 0.005). Non-hematological adverse events of Grade ≥ 3 were observed in 5 (16.7%) of 30 patients. One CRC patient experienced Grade 3 hemoptysis and another 2 experienced Grade 3 anaphylaxis. One patient with cholangiocellular carcinoma and gastric cancer experienced Grade 3 pseudomembranous colitis as a result of a Clostridium difficile infection. One patient (3.3%) died of pemetrexed-induced pneumonitis. The success of the anti-MTB chemotherapy was 70.0%. There were no MTB-related treatment failures. The median overall survival (months, 95.0% confidence interval) was 10.5 (8.7-36.7), 8.7 (4.7-10.0), 36.7 (minimum 2.2), and 14.4 (minimum 9.6) for all patients combined, LC, CRC, and Other malignancies, respectively. LC patients experienced delayed MTB diagnosis and shorter overall survival.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Concurrent chemotherapy is effective and safe for treating cancer patients with active MTB.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Hirashima</LastName>                    <ForeName>Tomonori</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan. hirashimat@ra.opho.jp.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tamura</LastName>                    <ForeName>Yoshitaka</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Clinical Laboratory, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Han</LastName>                    <ForeName>Yuki</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Infectious Diseases, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hashimoto</LastName>                    <ForeName>Shoji</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Infectious Diseases, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tanaka</LastName>                    <ForeName>Ayako</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shiroyama</LastName>                    <ForeName>Takayuki</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Morishita</LastName>                    <ForeName>Naoko</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Suzuki</LastName>                    <ForeName>Hidekazu</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Okamoto</LastName>                    <ForeName>Norio</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Thoracic Oncology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Akada</LastName>                    <ForeName>Shinobu</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Gynecology, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fujishima</LastName>                    <ForeName>Makoto</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Breast Surgery, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kadota</LastName>                    <ForeName>Yoshihisa</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Thoracic Surgery, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sakata</LastName>                    <ForeName>Kazuya</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Gastroenterological Surgery, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nishitani</LastName>                    <ForeName>Akiko</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Gastroenterological Surgery, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Miyazaki</LastName>                    <ForeName>Satoru</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Gastroenterological Surgery, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nagai</LastName>                    <ForeName>Takayuki</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Infectious Diseases, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>BMC Cancer</MedlineTA>            <NlmUniqueID>100967800</NlmUniqueID>            <ISSNLinking>1471-2407</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Nagoya J Med Sci. 2015 Feb;77(1-2):19-28</RefSource>                <PMID Version="1">25797967</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bull World Health Organ. 1974;51(1):71-82</RefSource>                <PMID Version="1">4218139</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nucleic Acids Res. 2000 Jun 15;28(12):E63</RefSource>                <PMID Version="1">10871386</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer. 2016 May;23(3):357-66</RefSource>                <PMID Version="1">27052720</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2000 Feb 2;92(3):205-16</RefSource>                <PMID Version="1">10655437</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2014 Oct 18;14:770</RefSource>                <PMID Version="1">25326267</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Clin Pharmacol. 2008 Jan;64(1):31-41</RefSource>                <PMID Version="1">18000659</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Compr Canc Netw. 2015 Oct;13(10):1225-31</RefSource>                <PMID Version="1">26483062</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62</RefSource>                <PMID Version="1">12588714</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Clin Oncol. 2015 Apr;20(2):207-39</RefSource>                <PMID Version="1">25782566</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Microbiol. 1995 Sep;33(9):2324-7</RefSource>                <PMID Version="1">7494021</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2007 Jul 16;97(2):162-9</RefSource>                <PMID Version="1">17579629</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Microbiol. 2002 Jan;40(1):150-4</RefSource>                <PMID Version="1">11773109</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Basic Clin Pharmacol Toxicol. 2005 Oct;97(4):249-56</RefSource>                <PMID Version="1">16176562</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Hepatobiliary Pancreat Surg. 2008;15(1):55-62</RefSource>                <PMID Version="1">18274844</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Semin Radiat Oncol. 2003 Jul;13(3):176-81</RefSource>                <PMID Version="1">12903007</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2010 Nov 1;28(31):4697-705</RefSource>                <PMID Version="1">20921465</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Infect Dis. 2006 Sep;6(9):570-81</RefSource>                <PMID Version="1">16931408</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S18-S19</RefSource>                <PMID Version="1">28043540</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2009 Apr 2;360(14):1408-17</RefSource>                <PMID Version="1">19339720</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Kekkaku. 2011 May;86(5):499-507</RefSource>                <PMID Version="1">21735857</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Tuberc Lung Dis. 2015 Feb;19(2):157-62</RefSource>                <PMID Version="1">25574913</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Colorectal cancer</Keyword>            <Keyword MajorTopicYN="N">Concurrent chemotherapy</Keyword>            <Keyword MajorTopicYN="N">Efficacy</Keyword>            <Keyword MajorTopicYN="N">Gastric cancer</Keyword>            <Keyword MajorTopicYN="N">Lung cancer</Keyword>            <Keyword MajorTopicYN="N">Safety</Keyword>            <Keyword MajorTopicYN="N">Tuberculosis</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>08</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30314434</ArticleId>            <ArticleId IdType="doi">10.1186/s12885-018-4889-1</ArticleId>            <ArticleId IdType="pii">10.1186/s12885-018-4889-1</ArticleId>            <ArticleId IdType="pmc">PMC6186130</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>